A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance

导出原文传递

翻译打印收藏纠错

作者： Akaza, Hideyuki ^[1] ; Oya, Mototsugu ^[2] ; Iijima, Masafumi ^[3] ; Hyodo, Ichinosuke ^[4] ; Gemma, Akihiko ^[5] ; Itoh, Hiroshi ^[6] ; Adachi, Masatoshi ^[7] ; Okayama, Yutaka ^[8] ; Sunaya, Toshiyuki ^[9] ; Inuyama, Lyo

作者单位： Showa Univ, Sch Med, Tokyo 142, Japan ^[1] Bayer Yakuhin Ltd, Med Affairs, Pharmacovigilance, Osaka, Japan ^[2] Keio Univ, Sch Med, Dept Internal Med, Div Endocrinol Metab & Nephrol, Tokyo, Japan ^[3] Bayer Yakuhin Ltd, Med Affairs Oncol & Hematol, Osaka, Japan ^[4] Univ Tokyo, Grad Sch Interdisciplinary Informat Studies, Interfac Initiat Informat Studies, Dept ^[5] Univ Tsukuba, Inst Clin Med, Grad Sch Comprehens Human Sci, Dept Gastroenterol & Hepatol, Tsukuba ^[6] Bayer Yakuhin Ltd, Clin Stat, Osaka, Japan ^[7] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan ^[8] Nippon Med Sch, Internal Med, Dept Pulm Med Infect & Oncol, Tokyo 113, Japan ^[9]

关键词 molecularly targeted therapy post-marketing surveillance renal cell carcinoma sorafenib tosylate

发布时间 2021-02-03

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交